Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ABOS)

Q: What does CUSIP 00509G209 represent in this 13F holders report?

CUSIP 00509G209 is the security identifier for ABOS - Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ABOS - Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share in Q2 2025?

69 institutional investors reported ABOS - Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 00509G209

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 72,227,200
Total 13F shares: 37,585,884
Share change: -1,849,867
Total reported value: $43,599,129
Put/Call ratio: 0%
Price per share: $1.16
Number of holders: 69
Value change: -$2,103,479
Number of buys: 31
Number of sells: 47

Quarterly Holders Quick Answers

What is CUSIP 00509G209?
CUSIP 00509G209 identifies ABOS - Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 00509G209:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ABOS - Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F	Company	21%	14,932,063	$16,425,269	—	31 Mar 2025	13F
Sands Capital Ventures Discovery Fund III, L.P.	3/4/5	10%+ Owner	— class O/S missing	3,417,075	$11,859,300	—	06 Jul 2021	3/4/5
James B. Murray Jr.	13D/G	—	5%	3,611,360	$9,425,650	$0	04 Apr 2025	13D/G
Sands Capital Alternatives, LLC	13D/G 13F	Company	5.6%	3,417,075	$3,861,295	$0	30 Jun 2025	13D/G 13F
FRANKLIN RESOURCES INC	13F	Company	4.4%	3,141,939	$3,456,133	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	3.2%	2,331,049	$2,564,155	—	31 Mar 2025	13F
Paul B. Manning	3/4/5	10%+ Owner	— class O/S missing	657,985	$2,283,603	—	06 Jul 2021	3/4/5
Robert D. Hardie	3/4/5	10%+ Owner	— class O/S missing	657,985	$2,283,603	—	06 Jul 2021	3/4/5
FMR LLC	13F	Company	2.8%	2,025,623	$2,228,185	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	2.7%	1,936,991	$2,130,690	—	31 Mar 2025	13F
Knollwood Investment Advisory, LLC	13F	Company	2.3%	1,628,510	$1,791,361	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	1.2%	832,267	$1,456,467	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.6%	1,135,222	$1,248,744	—	31 Mar 2025	13F
Pathstone Holdings, LLC	13F	Company	1.5%	1,086,531	$1,195,184	—	31 Mar 2025	13F
Alyeska Investment Group, L.P.	13F	Company	1.3%	939,603	$1,033,563	—	31 Mar 2025	13F
Laurion Capital Management LP	13F	Company	1.2%	867,046	$953,751	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.2%	861,899	$948,182	—	31 Mar 2025	13F
Hudson Bay Capital Management LP	13F	Company	1.1%	770,000	$847,000	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.72%	521,206	$573,327	—	31 Mar 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.64%	463,700	$510,070	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.4%	289,836	$318,820	—	31 Mar 2025	13F
Ikarian Capital, LLC	13F	Company	0.37%	265,769	$292,345	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.36%	256,700	$282,370	—	31 Mar 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.32%	232,293	$255,522	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.27%	196,207	$215,828	—	31 Mar 2025	13F
John A. Stalfort III	3/4/5	Director	— mixed-class rows	204,624 mixed-class rows	$203,636	—	04 Jun 2025	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.22%	158,934	$174,827	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.21%	152,636	$167,900	—	31 Mar 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.2%	146,183	$160,801	—	31 Mar 2025	13F
Invesco Ltd.	13F	Company	0.18%	127,798	$140,578	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.17%	123,015	$135,317	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.16%	116,902	$128,592	—	31 Mar 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.16%	115,171	$126,688	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.15%	110,976	$122,074	—	31 Mar 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.13%	96,995	$106,695	—	31 Mar 2025	13F
Bank of New York Mellon Corp	13F	Company	0.12%	90,258	$99,284	—	31 Mar 2025	13F
CATALYST FINANCIAL PARTNERS LLC	13F	Company	0.12%	89,699	$98,669	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.11%	78,446	$86,290	—	31 Mar 2025	13F
BARCLAYS PLC	13F	Company	0.1%	72,265	$79,491	—	31 Mar 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.07%	51,042	$56,146	—	31 Mar 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.06%	45,516	$50,064	—	31 Mar 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.06%	43,524	$47,876	—	31 Mar 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.06%	41,735	$45,909	—	31 Mar 2025	13F
Marex Group plc	13F	Company	0.05%	33,300	$36,630	—	31 Mar 2025	13F
Intrepid Financial Planning Group LLC	13F	Company	0.04%	30,150	$33,165	—	31 Mar 2025	13F
CITIGROUP INC	13F	Company	0.04%	29,836	$32,820	—	31 Mar 2025	13F
INTECH INVESTMENT MANAGEMENT LLC	13F	Company	0.04%	28,540	$31,394	—	31 Mar 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.04%	27,678	$30,446	—	31 Mar 2025	13F
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.03%	25,171	$27,688	—	31 Mar 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.03%	22,135	$24,349	—	31 Mar 2025	13F

Institutional Holders of Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ABOS) as of Q2 2025

As of 30 Jun 2025, Acumen Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ABOS) was held by 69 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 37,585,884 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., Sands Capital Alternatives, LLC, FRANKLIN RESOURCES INC, FMR LLC, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, Knollwood Investment Advisory, LLC, Pathstone Holdings, LLC, Alyeska Investment Group, L.P., and ADAR1 Capital Management, LLC. This page lists 70 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-10

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.